Pedro Pesini

Zaragoza, AR 50009, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 35 publications

The global Alzheimer's Association round robin study on plasma amyloid β methods.

The global Alzheimer's Association round robin study on plasma amyloid β methods.

Journal: Alzheimer's & dementia (Amsterdam, Netherlands)

Published: June 24, 2021

Performance of the plasma Aβ42/Aβ40 ratio, measured with a novel HPLC-MS/MS method, as a biomarker of amyloid PET status in a DPUK-KOREAN cohort.

Performance of the plasma Aβ42/Aβ40 ratio, measured with a novel HPLC-MS/MS method, as a biomarker of amyloid PET status in a DPUK-KOREAN cohort.

Journal: Alzheimer's research & therapy

Published: April 07, 2021

Detecting amyloid positivity in early Alzheimer's disease using combinations of plasma Aβ42/Aβ40 and p-tau.

Detecting amyloid positivity in early Alzheimer's disease using combinations of plasma Aβ42/Aβ40 and p-tau.

Journal: Alzheimer's & dementia : the journal of the Alzheimer's Association

Published: December 29, 2020

Individualized prognosis of cognitive decline and dementia in mild cognitive impairment based on plasma biomarker combinations.

Individualized prognosis of cognitive decline and dementia in mild cognitive impairment based on plasma biomarker combinations.

Journal: Nature aging

Published: July 10, 2020

Longitudinal evaluation of the natural history of amyloid-β in plasma and brain.

Longitudinal evaluation of the natural history of amyloid-β in plasma and brain.

Journal: Brain communications

Published: December 02, 2019

Plasma amyloid beta levels are associated with cerebral amyloid and tau deposition.

Plasma amyloid beta levels are associated with cerebral amyloid and tau deposition.

Journal: Alzheimer's & dementia (Amsterdam, Netherlands)

Published: August 07, 2019

Plasma Aβ42/40 ratio alone or combined with FDG-PET can accurately predict amyloid-PET positivity: a cross-sectional analysis from the AB255 Study.

Plasma Aβ42/40 ratio alone or combined with FDG-PET can accurately predict amyloid-PET positivity: a cross-sectional analysis from the AB255 Study.

Journal: Alzheimer's research & therapy

Published: July 11, 2019

Brain pyrimidine nucleotide synthesis and Alzheimer disease.

Brain pyrimidine nucleotide synthesis and Alzheimer disease.

Journal: Aging

Published: June 25, 2019

Total Aβ42/Aβ40 ratio in plasma predicts amyloid-PET status, independent of clinical AD diagnosis.

Total Aβ42/Aβ40 ratio in plasma predicts amyloid-PET status, independent of clinical AD diagnosis.

Journal: Neurology

Published: January 09, 2019

Plasma Aβ42/40 Ratio Detects Early Stages of Alzheimer's Disease and Correlates with CSF and Neuroimaging Biomarkers in the AB255 Study.

Plasma Aβ42/40 Ratio Detects Early Stages of Alzheimer's Disease and Correlates with CSF and Neuroimaging Biomarkers in the AB255 Study.

Journal: The journal of prevention of Alzheimer's disease

Published: December 21, 2018

Blood Markers in Healthy-Aged Nonagenarians: A Combination of High Telomere Length and Low Amyloidβ Are Strongly Associated With Healthy Aging in the Oldest Old.

Blood Markers in Healthy-Aged Nonagenarians: A Combination of High Telomere Length and Low Amyloidβ Are Strongly Associated With Healthy Aging in the Oldest Old.

Journal: Frontiers in aging neuroscience

Published: July 30, 2018

Correlations between plasma and PET beta-amyloid levels in individuals with subjective cognitive decline: the Fundació ACE Healthy Brain Initiative (FACEHBI).

Correlations between plasma and PET beta-amyloid levels in individuals with subjective cognitive decline: the Fundació ACE Healthy Brain Initiative (FACEHBI).

Journal: Alzheimer's research & therapy

Published: June 01, 2018

Showing 1-12 of 35

Last Updated: 09/26/2026